Selected Consolidated Financial Statement Information (Tables)

12 Months Ended

Jun. 30, 2018

Quarterly Financial Information Disclosure [Abstract]

Accounts receivable

	June 30,
	2018			2017
Accounts receivable	$	32,025		$	29,336
Less: Allowance for doubtful accounts	(800		)	(864		)
Accounts receivable, net	$	31,225		$	28,472

Inventories

	June 30,
	2018		2017
Raw materials	$	6,820	$	7,898
Work in process	1,315		1,221
Finished goods	8,470		7,778
Inventories	$	16,605	$	16,897

Property and equipment

	June 30,
	2018			2017
Land	$	500		$	500
Building	22,420			22,420
Equipment	16,510			16,502
Furniture	2,709			2,709
Leasehold improvements	438			86
Construction in progress	1,110			421
	43,687			42,638
Less: Accumulated depreciation	(15,943		)	(12,942		)
Total Property and equipment, net	$	27,744		$	29,696

Patents, net

	June 30,
	2018			2017
Patents	$	6,435		$	6,056
Less: Accumulated amortization	(1,204		)	(1,000		)
Total Patents, net	$	5,231		$	5,056

Patent amortization schedule

As of June 30, 2018, future estimated amortization of patents is as follows:

2019	$	199
2020	193
2021	191
2022	181
2023	174
Thereafter	4,293
	$	5,231

Accrued expenses

	June 30,
	2018		2017
Commissions	$	7,234	$	8,217
Salaries and bonus	6,624		8,247
Accrued vacation	3,557		3,436
Accrued excise, sales and other taxes	3,522		3,497
Legal settlement	1,847		1,814
Clinical studies	1,422		657
Accrued litigation	—		2,600
Other accrued expenses	1,570		1,768
Total Accrued expenses	$	25,776	$	30,236

Non-current other liabilities

	June 30,
	2018		2017
Legal settlement	$	467	$	2,314
Deferred compensation	395		519
Deferred grant incentive	460		473
Other liabilities	90		173
Total Other liabilities	$	1,412	$	3,479